Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus in early Lymphangioleiomyomatosis
NCT03150914Phase 3Active, not recruiting
- Sponsor
- University of Cincinnati
- Start
- Jan 2018
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lymphangioleiomyomatosis (LAM) comparing Sirolimus with Placebo (2 arms). Primary endpoint: Rate of change in Forced Expiratory Volume in 1 Second at 2 years. Started Jan 2018; status: active, not recruiting.
02
Drugs
sirolimus
03
Conditions
lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on NCT03150914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150914.